SM
CLDX icon

SG3 Management’s Celldex Therapeutics CLDX Stock Holding History

SG3 Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,500
Closed -$676K – 1018
2021
Q4 		$676K Sell
17,500
-6,000
-26% -$261K 0.01% 565
2021
Q3 		$1.27M Buy
+23,500
New +$1.1M 0.04% 407

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SG3 Management's CLDX Position: Q1 2022 in Review

SG3 Management sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 17,500 shares — an estimated $676K sold.

SG3 Management first reported a position in CLDX in Q3 2021 and held it in 2 quarters. The position peaked at $1.27M in Q3 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

  • SG3 Management reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 17,500 Celldex Therapeutics shares in Q1 2022, an estimated $676K.
  • SG3 Management first reported a position in Celldex Therapeutics in Q3 2021 and held it in 2 quarters.
  • SG3 Management's Celldex Therapeutics position peaked at $1.27M in Q3 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.